Literature DB >> 31606760

The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma.

Ho Won Kang1,2, Sung Min Kim1, Won Tae Kim1,2, Seok Joong Yun1,2, Sang-Cheol Lee1,2, Wun-Jae Kim1,2, Eu Chang Hwang3, Seok Ho Kang4, Sung-Hoo Hong5, Jinsoo Chung6, Tae Gyun Kwon7, Hyeon Hoe Kim8, Cheol Kwak8, Seok-Soo Byun9, Yong-June Kim10,11.   

Abstract

PURPOSE: No study has evaluated the prognostic impact of the age-adjusted Charlson comorbidity index (AACI) in those with renal cell carcinoma (RCC). This study aimed to evaluate the utility of the AACI for predicting long-term survival in patients with surgically treated non-metastatic clear cell RCC (ccRCC).
METHODS: Data from 698 patients with non-metastatic ccRCC who underwent radical or partial nephrectomy as primary therapy from a multi-institutional Korean collaboration between 1988 and 2015 were retrospectively analyzed. Clinicopathological variables and survival outcomes of those with AACI scores ≤ 3 (n = 324), 4-5 (n = 292), and ≥ 6 (n = 82) were compared.
RESULTS: Patients with a high AACI score were older and more likely to be female. They were also more likely to have diabetes or hypertension, a worse Eastern Cooperative Oncology Group performance status, and lower preoperative hemoglobin, albumin, serum calcium, and serum total cholesterol levels. Regarding pathologic features, a high AACI score was associated with advanced stage. Kaplan-Meier analyses revealed that AACI ≥ 6 was associated with shorter cancer-specific (log-rank test, P < 0.001) and overall survival (log-rank test, P < 0.001), but not with recurrence-free survival (log-rank test, P = 0.134). Multivariate Cox regression analyses identified an AACI score as an independent predictor of overall survival (hazard ratio, 6.870; 95% confidence interval, 2.049-23.031; P = 0.002). The AACI score was a better discriminator of overall survival than the Charlson comorbidity index score.
CONCLUSIONS: AACI scores may enable more tailored, individualized management strategies for patients with surgically treated non-metastatic ccRCC.

Entities:  

Keywords:  Comorbidity; Nephrectomy; Prognosis; Renal cell carcinoma; Survival

Mesh:

Year:  2019        PMID: 31606760     DOI: 10.1007/s00432-019-03042-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  30 in total

Review 1.  Measurement and impact of comorbidity in older cancer patients.

Authors:  M Extermann
Journal:  Crit Rev Oncol Hematol       Date:  2000-09       Impact factor: 6.312

2.  Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Robert J Motzer; Eric Jonasch; Neeraj Agarwal; Sam Bhayani; William P Bro; Sam S Chang; Toni K Choueiri; Brian A Costello; Ithaar H Derweesh; Mayer Fishman; Thomas H Gallagher; John L Gore; Steven L Hancock; Michael R Harrison; Won Kim; Christos Kyriakopoulos; Chad LaGrange; Elaine T Lam; Clayton Lau; M Dror Michaelson; Thomas Olencki; Phillip M Pierorazio; Elizabeth R Plimack; Bruce G Redman; Brian Shuch; Brad Somer; Guru Sonpavde; Jeffrey Sosman; Mary Dwyer; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2017-06       Impact factor: 11.908

3.  Comorbidity and Survival in Lung Cancer Patients.

Authors:  K M Monirul Islam; Xiaqing Jiang; Trisari Anggondowati; Ge Lin; Apar Kishor Ganti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-11       Impact factor: 4.254

4.  Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.

Authors:  Rudy S Suidan; Mario M Leitao; Oliver Zivanovic; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Douglas A Levine; Elizabeth L Jewell; Carol L Brown; Nadeem R Abu-Rustum; Mary E Charlson; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2015-05-31       Impact factor: 5.482

5.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  B Escudier; C Porta; M Schmidinger; N Rioux-Leclercq; A Bex; V Khoo; V Gruenvald; A Horwich
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

6.  Impact of Charlson's comorbidity index on overall survival following tumor nephrectomy for renal cell carcinoma.

Authors:  M Hammad Ather; Syed M Nazim
Journal:  Int Urol Nephrol       Date:  2009-08-28       Impact factor: 2.370

7.  Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index.

Authors:  Daniel Santos Arrontes; María Jesús Fernández Aceñero; Jesús Isidoro García González; Manuel Martín Muñoz; Pedro Paniagua Andrés
Journal:  J Urol       Date:  2008-01-25       Impact factor: 7.450

8.  Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study.

Authors:  Ho Won Kang; Sung Pil Seo; Won Tae Kim; Yong June Kim; Seok Joong Yun; Sang Cheol Lee; Young Deuk Choi; Yun Sok Ha; Tae Hwan Kim; Tae Gyun Kwon; Seok Soo Byun; Seong Uk Jeh; Wun Jae Kim
Journal:  J Korean Med Sci       Date:  2017-02       Impact factor: 2.153

9.  Adjusted Age-Adjusted Charlson Comorbidity Index Score as a Risk Measure of Perioperative Mortality before Cancer Surgery.

Authors:  Chun-Ming Chang; Wen-Yao Yin; Chang-Kao Wei; Chin-Chia Wu; Yu-Chieh Su; Chia-Hui Yu; Ching-Chih Lee
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

10.  Impact of Young Age at Diagnosis on Survival in Patients with Surgically Treated Renal Cell Carcinoma: a Multicenter Study.

Authors:  Ho Won Kang; Sung Pil Seo; Won Tae Kim; Seok Joong Yun; Sang Cheol Lee; Wun Jae Kim; Eu Chang Hwang; Seok Ho Kang; Sung Hoo Hong; Jinsoo Chung; Tae Gyun Kwon; Hyeon Hoe Kim; Cheol Kwak; Seok Soo Byun; Yong June Kim
Journal:  J Korean Med Sci       Date:  2016-12       Impact factor: 2.153

View more
  6 in total

1.  Effect of the Age-Adjusted Charlson Comorbidity Index on All-Cause Mortality and Readmission in Older Surgical Patients: A National Multicenter, Prospective Cohort Study.

Authors:  Xiao-Ming Zhang; Xin-Juan Wu; Jing Cao; Na Guo; Hai-Xin Bo; Yu-Fen Ma; Jing Jiao; Chen Zhu
Journal:  Front Med (Lausanne)       Date:  2022-06-28

2.  Higher Charlson Comorbidity Index Increases 90-Day Readmission Rate with Poorer Functional Outcomes in Surgically Treated Hip Fracture Patients.

Authors:  Cheryl Gatot; Evan Shern-En Tan; Ming Han Lincoln Liow; Jerry Yongqiang Chen; Meng Ai Png; Mann Hong Tan; Tet Sen Howe; Joyce Suang Bee Koh
Journal:  Geriatr Orthop Surg Rehabil       Date:  2021-08-13

3.  The Four-Feature Prognostic Models for Cancer-Specific and Overall Survival after Surgery for Localized Clear Cell Renal Cancer: Is There a Place for Inflammatory Markers?

Authors:  Łukasz Zapała; Aleksander Ślusarczyk; Rafał Wolański; Paweł Kurzyna; Karolina Garbas; Piotr Zapała; Piotr Radziszewski
Journal:  Biomedicines       Date:  2022-05-23

4.  Quality of Recovery After General Anesthesia with Remimazolam in Patients' Undergoing Urologic Surgery: A Randomized Controlled Trial Comparing Remimazolam with Propofol.

Authors:  Yuanyuan Mao; Jin Guo; Jingjing Yuan; Erxian Zhao; Jianjun Yang
Journal:  Drug Des Devel Ther       Date:  2022-04-27       Impact factor: 4.319

5.  Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy.

Authors:  Xianghua Zeng; Shicong Zhu; Cheng Xu; Zhongyu Wang; Xingxing Su; Dong Zeng; Haixia Long; Bo Zhu
Journal:  Med Sci Monit       Date:  2020-09-07

6.  Nucleolar protein NOP2 could serve as a potential prognostic predictor for clear cell renal cell carcinoma.

Authors:  Gang Wang; Fangfang Qu; Shouyong Liu; Jincai Zhou; Yi Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.